Compare ASTRAZENECA PHARMA with FDC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FDC - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FDC ASTRAZENECA PHARMA/
FDC
 
P/E (TTM) x 108.7 16.5 658.2% View Chart
P/BV x 14.6 2.4 605.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 ASTRAZENECA PHARMA   FDC
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-21
FDC
Mar-21
ASTRAZENECA PHARMA/
FDC
5-Yr Chart
Click to enlarge
High Rs4,970378 1,314.8%   
Low Rs2,348191 1,229.4%   
Sales per share (Unadj.) Rs325.479.0 412.1%  
Earnings per share (Unadj.) Rs37.317.8 209.2%  
Cash flow per share (Unadj.) Rs45.420.1 225.9%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.10-  
Book value per share (Unadj.) Rs181.8102.7 177.0%  
Shares outstanding (eoy) m25.00168.81 14.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x11.23.6 312.1%   
Avg P/E ratio x98.015.9 614.9%  
P/CF ratio (eoy) x80.614.2 569.2%  
Price / Book Value ratio x20.12.8 726.6%  
Dividend payout %5.40-   
Avg Mkt Cap Rs m91,47848,026 190.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1952,963 74.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m8,13613,332 61.0%  
Other income Rs m128970 13.2%   
Total revenues Rs m8,26414,302 57.8%   
Gross profit Rs m1,3553,319 40.8%  
Depreciation Rs m201378 53.2%   
Interest Rs m1134 31.7%   
Profit before tax Rs m1,2713,877 32.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m338865 39.1%   
Profit after tax Rs m9333,012 31.0%  
Gross profit margin %16.724.9 66.9%  
Effective tax rate %26.622.3 119.1%   
Net profit margin %11.522.6 50.8%  
BALANCE SHEET DATA
Current assets Rs m6,88713,521 50.9%   
Current liabilities Rs m3,7346,223 60.0%   
Net working cap to sales %38.854.7 70.8%  
Current ratio x1.82.2 84.9%  
Inventory Days Days45307 14.7%  
Debtors Days Days38303 12.6%  
Net fixed assets Rs m1,85513,033 14.2%   
Share capital Rs m50169 29.6%   
"Free" reserves Rs m4,49617,173 26.2%   
Net worth Rs m4,54617,341 26.2%   
Long term debt Rs m02 0.0%   
Total assets Rs m8,74226,554 32.9%  
Interest coverage x117.6113.9 103.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.5 185.4%   
Return on assets %10.811.5 94.1%  
Return on equity %20.517.4 118.2%  
Return on capital %28.222.6 125.0%  
Exports to sales %00-   
Imports to sales %29.34.1 708.4%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m2,382551 432.3%   
Fx inflow Rs m3183,254 9.8%   
Fx outflow Rs m2,382551 432.3%   
Net fx Rs m-2,0642,703 -76.4%   
CASH FLOW
From Operations Rs m1,0482,071 50.6%  
From Investments Rs m1,730-772 -224.3%  
From Financial Activity Rs m-90-1,293 6.9%  
Net Cashflow Rs m2,6886 48,439.6%  

Share Holding

Indian Promoters % 0.0 69.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.6 10.4 34.4%  
FIIs % 2.4 4.5 52.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 30.6 81.6%  
Shareholders   57,760 86,503 66.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

SGX Nifty Trades Flat, Maruti Suzuki Acquires Stake in AI Firm, Zomato Q4 Results, and Top Buzzing Stocks Today(Pre-Open)

On Monday, Indian share markets failed to keep up early gains and ended marginally lower.

Related Views on News

4 Indian Companies Executing Big Buyback Plans (Views On News)

Mar 5, 2022

Share buybacks can create value for shareholders while companies can deploy capital to achieve attractive returns.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 23, 2022 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS